TNFRSF9 and neoplasm: We have previously reported that antitumor immunotherapy elicited by anti‐CD137 and anti‐PD‐1 mAbs was totally dependent on the performance of cDC1 cells in tumor antigen crosspriming (Sanchez‐Paulete et al, 2016).